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Abstract
Background: Parkinson’s disease (PD) is a common heterogeneous neurodegenerative disorder in elder population.
Parkinson’s disease dementia (PDD) is one of the most common non-motor manifestations in PD patients.
No comprehensive review has been conducted to assess risk factors for PDD.
Methods: A systemic search for studies on PDD risk factors was performed. Cohort and case–control studies
that clearly defined PDD and presented relevant data were included. The data were analyzed to generate a
pooled effect size and 95 % confidence interval (CI). Publication bias was assessed using the Egger’s test and
the Begg’s test.
Results: A systematic search was conducted and yielded 5195 articles. After screening, 25 studies were included in the
current analysis. Development of PDD was positively associated with age (odds ratio [OR] 1.07, 95 % CI 1.03-1.13), male
(OR 1.33, 95 % CI 1.08-1.64), higher Unified Parkinson’s Disease Rating Scale (UPDRS) part III scores (relative risk [RR] 1.04,
95 % CI 1.01-1.07), hallucination (OR 2.47, 95 % CI 1.36-4.47), REM sleep behavior disorder (RBD) (OR 8.38, 95 % CI
3.87-18.08), smoking (ever vs. never) (RR 1.93, 95 % CI 1.15-3.26) and hypertension (OR 1.57, 95 % CI 1.11-2.22).
An inverse association was found between education (RR 0.94, 95 % CI 0.91-0.98) and PDD. Other reported factors,
including age of onset, disease duration of PD, Hoehn and Yahr stage and diabetes mellitus were not significantly
associated with PDD.
Conclusions: Advanced age, male, higher UPDRS III scores, hallucination, RBD, smoking and hypertension increase the
risk of PDD, whereas higher education is a protective factor for PDD.
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Background
Parkinson’s disease (PD), a heterogeneous neurodegenera-
tive disorder in elder population, is characterized by car-
dinal motor symptoms including bradykinesia, rigidity,
tremor and postural instability [1]. Recently, increasing
evidence shows that PD is a disease with many non-motor
symptoms (NMS) including dementia, sleep disorders,
mood disorders, urinary dysfunction, and olfactory disor-
ders [2]. Among NMS, Parkinson disease dementia (PDD)
is one of the most common symptoms with a mean preva-
lence of 31.3 % in PD patients [3]. Among general popula-
tion, PDD incidence rate is approximately 38.7 to 112.5
per 1000 person-year among several cohort studies con-
ducted in different regions [3, 4]. It has been suggested
that PD patients who developed dementia tend to have in-
creased health care burden, declined quality of life and in-
creased mortality [5–7]. However, effective treatment for
PDD is currently unclear [8]. Being able to predict PDD
development accurately would provide opportunities for
intervention as well as novel treatments and might pro-
long survival [9].
Several demographic, motor and non-motor features
have been identified as predictors for PDD. Advanced age
is the most common risk factor for dementia and for later
diagnosis of PDD in PD patients [10]. More advanced dis-
ease stage as well as specific Parkinson subtype, the
akinetic-rigid subtype, was found to be associated with in-
creased risk for PDD, whereas the evaluation scales are
not coherent [11, 12]. Some studies suggested that REM
sleep behavior disorder (RBD), hallucination, mood disor-
ders and olfactory dysfunction are strong predictors for
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PDD, but the results were not consistent across studies
[13–15]. Up to date, no comprehensive meta-analysis on
clinical risk factors for PDD has been conducted. A 2014
review on the predictors of PDD by Moore et al. summa-
rized major study results on different risk factors, includ-
ing clinical predictors, biological predictors, neuroimaging
predictors and genetic predictors [9]. In that previous re-
view, the authors presented all possible influences of those
factors on PDD, but did not provide quantitative evalu-
ation of the predictors. In order to quantitatively evaluate
the effects of different factors on PDD, we conducted this
systematic review and meta-analysis via an extensive




We conducted the search according to the Preferred
Reporting Items for Systematic Review and Meta-analysis
(PRISMA 2009) guideline. We searched MEDLINE and
EMBASE database for studies reporting predictors for
later diagnosis of PDD. No language restrictions were
used. The keywords we selected were: “Parkinson Dis-
ease” AND “Dementia” AND “Risk” OR “Predict” OR
“Age” OR “Age of Onset” OR “Education” OR “Family
history” OR “Hallucination” OR “Sleep Disorders” OR
“Constipation” OR “Olfactory Disorders” OR “Color Vi-
sion” OR “Depression” OR “Anxiety” OR “Mood Disor-
ders” OR “Erectile Dysfunction” OR “Urinary Dysfunction”
OR “Hypertension” OR “Coronary Artery Disease” OR
“Head Injury” OR “Diabetes Mellitus” OR “Smoking” OR
“Alcohols” OR “Coffee” OR “Pesticides”. We also hand
searched the reference lists of relevant reviews and articles
with required data for missed references. The final search
was carried out on December 1, 2015.
Inclusion criteria
We included articles that met the predefined criteria:
1) cohort or case–control studies assessed at least one
risk factor preceding a later diagnosis of PDD; 2) com-
pared PDD patients with PD patients who did not de-
velop dementia; 3) clearly stated diagnostic criteria for
PD and PDD, and carried out by an experienced clin-
ician; 4) reported odds ratio (OR), relative risk (RR) or
equivalent values representing risks of developing de-
mentia or case–control studies with cases defined as
diagnosed PDD; and 5) reported data that could be eas-
ily obtained via questionnaires.
Exclusion criteria
Reviews, editorials, case reports, commentaries, letters
that reported no new data, meta-analysis, handouts, and
abstracts were excluded from the study. We excluded
studies that: 1) reported on treatment or management of
PDD; 2) reported a diseases other than PDD or PD; 3)
studied only young onset PD; 4) did not use a PD non-
demented group as comparable group to PDD group or
did not provide adequate data on the comparable group;
5) were twin studies; 6) reported one predictor repeatedly
in one study population (if >1 paper reported on one
study population, we chose the larger one, and where
population is equal, we chose the most recent one); 7) re-
ported on predictors that were not easily available in most
clinical settings (i.e. questionnaires designed for a certain
population or country); 8) reported only uncommon gen-
etic risk factors; 9) reported measures other than OR, RR
or equivalent values, or from which an OR could not be
calculated. Two authors (X.Y. and J.Y.) independently
evaluated the eligibility of all studies, and if there was dis-
agreement between authors, the articles were further eval-
uated by a third author (H.S.) and discussed in detail until
an agreement has been reached.
Data extraction and quality assessment
Study characteristics, PDD diagnostic criteria, a risk esti-
mate of the main study finding, and secondary findings
were extracted using a unified form. We did not include
studies that reported dementia before or within one year
to the onset of PD, since these cases did not fulfill the
diagnostic criteria for PDD and were more likely cases
of dementia with Lewy bodies (DLB). If studies did not
report OR, RR or equivalent measures, raw data were
screened to determine whether ORs could be calculated.
When the studies reported both the crude OR/RRs and
the adjusted OR/RRs, the adjusted figures were extracted.
We calculated a quality score to assess the quality of the
studies according to the Newcastle-Ottawa Scale (NOS).
Length of time that any predictor precedes the diagnosis
of PDD was not analyzed in the study due to inconsistent
reporting.
Statistical analysis
We combined the reported risks first separately for
case–control and cohort studies, and second for all stud-
ies together, in cases where two or more studies reported
on the same factor. The data were analyzed to generate
a pooled effect size and 95 % confidence interval (CI).
We examined the heterogeneity across studies using the
I2 statistic [16, 17]. Where statistically significant hetero-
geneity was found (p < 0.05), we used randomized effects
model to combine results. We assessed publication bias
using the Egger’s test and the Begg’s test, and con-
structed funnel plot in order to visualize any possible
asymmetry [18]. Two-tailed P values less than 0.05 were
considered statistically significant. All analyses were
performed using Stata version 12.0 (StataCorp, College
Station, TX).
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Results
The electronic search yielded 5195 articles, all of which
were reviewed by titles and abstracts. Full text of 278 ar-
ticles were reviewed, of which 23 articles met the inclu-
sion criteria. We also hand searched the references of
the articles, 2 of which were included into the analysis.
Finally, a total of 25 articles were included in the meta-
analysis. Full details of the studies included were pro-
vided (Additional files 1 and 2). The selection process is
shown in a flow diagram (Fig. 1).
We found age (OR 1.07, 95 % CI 1.03-1.13), gender
(Male) (OR 1.33, 95 % CI 1.08-1.64) and hypertension
(OR 1.57, 95 % CI 1.11-2.22), to be significantly associated
with later diagnosis of PDD (Fig. 2), whereas age of onset
(AOO) (RR 1.03, 95 % CI 0.97-1.09), disease duration of
PD (RR 1.00, 95 % CI 0.96-1.03), and type 2 diabetes melli-
tus (OR 1.16, 95 % CI 0.58-2.42) were not associated with
risk of PDD (Fig. 3). Although education was only re-
ported in three cohort studies, it was the only factor we
found to decrease PDD risk (RR 0.94, 95 % CI 0.91-0.98)
(Fig. 3). Lifestyle related risk factors were poorly reported.
Previous and current smokers were reported to have
increased risk of developing PDD (RR 1.88, 95 % CI
1.06-3.34) comparing with non-smoking PD population.
However, alcohol consumption (RR 1.1, 95 % CI 0.6-2.2)
and coffee consumption (RR 0.9, 95 % CI 0.5-1.8), re-
ported in one study population, was not a significant risk
factor for PDD [19].
Two general scales evaluating PD patient’s motor fea-
tures were included in this study. Our result showed that
higher score in Unified Parkinson’s Disease Rating Scale
(UPDRS) part III (RR 1.04, 95 % CI 1.01-1.07) increased
the risk of PDD, but higher Hoehn and Yahr stage (RR
1.24, 95 % CI 0.92-1.66) was not associated with the devel-
opment PDD. Studies analyzing the association between
PD motor subtypes and PDD were not included in the
present meta-analysis because of limited data. Two com-
mon non-motor symptoms of PD patients, hallucination
(OR 2.47, 95 % CI 1.36-4.47) and RBD (OR 8.38, 95 % CI
3.87-18.08), were both strong predictors of PDD. Single
studies also reported positive association between PDD
and family history of dementia (first-degree relatives),
urinary dysfunction, impaired color vision or orthostatic
blood pressure drop and no significant association be-
tween family history of PD (first-degree relatives), expos-
ure to pesticides, occupational exposure to chemicals and
PDD [13, 15, 20]. Details of factors not included in the
meta-analysis were provided (Additional file 3).
Assessment of publication bias
The funnel plot for each included factors were individually
examined visually. The shape was presented essentially
symmetrical in age, AOO, gender, smoking, disease dur-
ation, education, UPDRS III, hallucination, RBD, hyper-
tension, diabetes mellitus and Hoehn and Yahr stage,
which was proved by Begg’s and Egger’s test.
Fig. 1 Flowchart of study selection; PDD = Parkinson Disease Dementia
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Discussion
This study identified 12 individual predictors that have
potential value in screening for PDD. The identified risk
factors include demographic characteristics, lifestyle fac-
tors, non-motor features of PD, and widely accepted
scales evaluating PD. Some of the factors may present
pathogenic importance while others could represent the
relationship between symptoms and cognitive decline.
Together, these factors tend to be markers preceding
diagnosis of PDD in PD patients. Of the identified fac-
tors, 7 factors were significant predictors for subsequent
diagnosis of PDD, the understanding of which may con-
tribute to higher quality of care and improve quality of
life in PD patients.
Age, AOO and disease duration were all common risk
factors for PDD. However, since these three factors are
Fig. 2 Factors that show significant positive association with PDD; RBD = REM sleep behavior disorder; CI = confidence interval; RR = relative risk;
OR = odds ratio
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interdependent, their individual effect on PDD is under
debate. One study comparing early and late onset PD pa-
tients suggested that late onset PD group presents with
more severe impaired sensory abilities, sleep disorders and
dementia [21]. Another study adjusted cofounding found
that among the three factors, only age remained an inde-
pendent risk factor for PDD [22]. Similarly, we found that
older age had a significant influence on later diagnosis of
PDD, while AOO and disease duration was not associated
with PDD. Our study suggested that advanced age as a
risk factor for PDD may be independent from PD related
time factors, like AOO or disease duration. Many neuro-
pathological studies have provided evidences on the effect
of aging. Recent studies with α-synuclein immunostaining
found a strong association between the age-related in-
crease of Lewy bodies in cortical areas and the develop-
ment of PDD [23, 24]. Another study found that cortical
amyloid-β deposition and aging together might be as-
sociated with PDD [25]. Few other studies revealed
that MAPT genotype, related with tau transcription,
has a strong influence on the risk of PDD [26, 27].
Goris et al. found that, among MAPT haplotypes, PD
patients with H1 homozygotes had an increased rate of
cognitive decline, which was dependent on age [28, 29].
These age-related pathological processes together may in-
crease the risk of PDD with aging.
We also found male to be a risk factor for PDD. How-
ever, some studies suggested that there might be no
relationship between gender and PDD if potential con-
founding factors, including age, history of dementia,
smoking and number of siblings, were adjusted [20, 22].
In the present meta-analysis, all data included for the
factor gender were unadjusted data. Therefore, our study
illustrated that male, before adjustment, is a positive pre-
dictor for PDD, but provided no evidence on the results
after confounding factors were adjusted. The only pro-
tective factor we found in the current meta-analysis is
higher education. Similar with our results, one study
found that when compared with elementary school level,
PDD patients with university level education were at
lower risk of developing dementia [30]. One possible ex-
planation is that education might modify the risk of cog-
nitive decline by greater functional brain reserve in PD
patients [31]. However, in a recent systematic review
looking into education and dementia in Alzheimer’s dis-
ease (AD), the authors suggested that although lower
education is associated with greater risk of dementia, the
findings varied by region, age, gender and ethnicity [32].
The association between education and dementia in PD
also need further studying with confounding adjusted.
A recent meta-analysis on risk factors for PD suggested
that smoking, alcohol and coffee consumption decreases
the risk of PD [33]. In the current meta-analysis we found
that a history of smoking increased the risk of dementia in
PD by almost two fold. On the other hand, alcohol and cof-
fee consumption has been reported to have no significant
Fig. 3 Factor that shows significant negative association with PDD and factors that show no significant association with PDD; CI = confidence
interval; RR = relative risk; OR = odds ratio
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association with PDD [19]. Smoking, different from alco-
hol and coffee consumption, stand as an independent risk
factor for PDD. One possible mechanism is related with
vascular factors. We found that hypertension was associ-
ated with PDD while diabetes was not significantly associ-
ated with PDD. Because smoking is also a risk factor for
hypertension and that hypertension is related with AD-
type pathologies in dementia, it is possible that smoking
affect dementia in PD via vascular route [34, 35]. However,
after adjustment for the possibility of confounding vascu-
lar factors in one included study, smoking still exists as an
increased risk for PDD [19]. Biologically, greater depletion
of cholinergic cells in the nucleus basalis of Meynert has
been observed in PDD [36], yet the up-regulation of cen-
tral nicotine acetylcholine receptors by nicotine contrasts
the mechanism [37, 38]. Another published meta-analysis
found that smoking was also a cause of cognitive decline
in AD patients as well as in patients with other dementia,
in which the authors suggested that non-smokers have
lower inflammation or oxidative stress that may lead to a
reduction in cognitive decline [39, 40].
We found that higher UPDRS III score was positively re-
lated with later diagnosis of PDD, whereas Hoehn and
Yahr stage was not significantly associated with PDD. This
result suggests that severe motor dysfunction is associated
with PDD risk, and that the risk is more likely associated
with individual motor dysfunctions. In a study that discov-
ered no significant association between UPDRS III and
PDD, researchers found that within the UPDRS III section,
gait dysfunction was strongly associated with eventual de-
velopment of dementia [13]. Gait dysfunction is important
for the classification of the postural instability and gait dif-
ficulties (PIGD) subtype, and several longitudinal studies
have discovered that 25 % to 64.9 % of PIGD PD patients
would be diagnosed with PDD by the end of follow-up
[11, 12]. Also, researchers have found that increased loss
of cholinergic nuclei may relate with both cognitive de-
cline and motor features including rigidity, gait, and bal-
ance [12, 41]. However, only two studies were evaluated
regarding Hoehn and Yahr stage, the result should be
interpreted with caution.
We discovered RBD and hallucination are strongly asso-
ciated with later diagnosis of PDD. Several studies sug-
gested that patients with RBD had a higher rate of MCI at
baseline and a shorter duration towards diagnosis of de-
mentia [42–44]. Cholinergic deficit due to degeneration of
ascending pathway that took place in both RBD and de-
mentia with Lewy bodies might be the cause [45]. Visual
hallucinations were also discovered to have positive associ-
ation with cognitive impairment in early PD [46]. In terms
of mechanism, pathological studies in PD indicated that
visual hallucination might share common limbic pathology
with cognitive decline and dementia [14]. In functional
MRI assessment, preceding image recognition, patients
with visual hallucinations have reduced activation in ven-
tral/lateral visual associated cortices [47]. However, a re-
verse relation was found in previous study suggesting that
cognitive impairment at baseline precedes later develop-
ment of hallucination [48]. Both RBD and hallucination
were also associated with MCI, an important predictor for
PDD [49, 50], in early Parkinson disease [42, 46]. None of
the studies included in our meta-analysis adjusted RBD or
hallucination for baseline cognitive impairment, therefore
the causal relation is unclear from the present study.
Limitations
We only selected factors that were easily obtained in pri-
mary care environment. Variables that used less common
inventories, like color vision and olfactory dysfunction,
were not included in the analysis. Also, genetic tests have
been excluded from the analysis for similar reasons. Mild
cognitive impairment, an important risk factor of inci-
dence dementia in PD [50, 51], was not included in the
meta-analysis because most studies on mild cognitive im-
pairment used a different group strategy by separating the
participants into PD-normal cognition, PD-mild cognitive
impairment and PDD group, which differs from most of
other PDD risk factor studies. Motor subtypes were not
analyzed in this meta-analysis also because of differences
in group strategy.
Not all studies adjusted risk factors for confounders,
and those adjusted were mostly adjusted for different con-
founders. We included both factors unadjusted and fac-
tors adjusted where possible, which may have increased
the degree of significance for some risk factors. Few fac-
tors were reported in studies to be positively associated or
not associated with later diagnosis of PDD but without
specified OR or RR to be extracted. Though we have cal-
culated OR or RR where possible, there may still be data
neglected.
Statistically significant heterogeneity was found in 8 of
the meta-analyses performed in our study. Two risk fac-
tors, age and AOO, were found to have high heterogeneity
(I2 > 75 %). Gender, education, hallucination, UPDRS III,
RBD and hypertension were found to have moderate het-
erogeneity (50 % < I2 < 75 %). The presence of heterogen-
eity was as expected because of the differences in the
characteristics of studies, the length of follow-up, study
population scale, population characteristics, diagnostic cri-
teria used and whether factors were crude or adjusted.
The follow-up period in the cohort studies and the diag-
nostic criteria for PDD in both cohort and case–control
studies varied, we did not adjust these factors in this
meta-analysis due to limited number of included stud-
ies. Thus, the results of this analysis should be inter-
preted cautiously, especially for those factors that were
reported in less than three studies and that were with
high heterogeneities.
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In the present meta-analysis, we included studies with
NOS score higher than 5, which ensured study quality.
Also, we performed sub-group analysis by different study
design in order to minimize heterogeneity. We combined
analytical results according to the heterogeneity analysis,
and did not find significant publication bias. Therefore,
our results were considered to be robust.
Conclusions
This is the first systematic review and meta-analysis on
widely evaluated risk factors of PDD. This study found
advanced age, male, high UPDRS III scores, presence of
hallucination, presence of RBD, ever smoking and his-
tory of hypertension are positive predictors to later diag-
nosis of PDD, whereas education is a protective factor of
PDD. This study laid the foundation to future compara-
tive assessment on risk factors for PDD, and lead to a
better understanding of PDD risks.
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